Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma


Disclosures: JJLB and PWHIP are employees of Genmab BV Utrecht, TM, HML, NWCJD, ACMM, RWJG received project grant support from Genmab and Janssen and HML and NWCJD also from Celgene. HY and JB are employees at Xpand Biotechnology. ED, WAN, JK, ZS and MT have nothing to disclose.

Contributions: ED performed the research, analyzed the data, and wrote the manuscript; RWJG, WAN, MT and ACMM assisted the design and the execution of the in vitro and in vivo experiments, analyzed the data and provided technical assistance; JK and ZS provided the retroviral construct and reviewed the manuscript; HY, JB provided the scaffolds for the in vivo experiments. JJLB, PWHIP provided the CD38 antibodies, assisted the design of the study, analyzed the data and reviewed the manuscript; NWCJD, HML and TM designed and supervised the research and wrote the manuscript.